
The area with the best data
Can early diagnostics prevent heart disease?
Partly yes. Cardiovascular disease is the one area of prevention where the full chain from measurement through treatment to a better outcome is evidenced in randomised trials. This page states which values deliver that and which do not.
26
randomised trials behind the central finding
~1/5
fewer major vascular events per 1 mmol/l LDL
1x
Lp(a) per lifetime, never again after that
The short answer
Yes — but it is not the measurement that prevents anything
An analysis of 26 randomised trials with around 170,000 participants shows: lowering LDL cholesterol by 1 mmol/l reduces the rate of major vascular events by roughly a fifth. The same pattern holds for blood pressure. That is why the answer here is yes, while on our other prevention pages it is often no.
The mechanism matters, because it often gets blurred: the diagnostics itself prevents no heart attack. It identifies the people in whom an effective treatment achieves something, and it identifies them early enough. Without the treatment that follows, the measurement is a data point with no effect.
What actually counts
Four measures that change a decision
Not every cardiac value changes a treatment. These do, and together they are neither expensive nor elaborate.
ApoB
Counts the number of atherogenic particles rather than only the amount of cholesterol transported. At the same LDL value the particle count can differ considerably, and it is the count that drives risk.
Lp(a)
Genetically determined and largely constant over life. The European societies therefore recommend measuring it once in adult life. Anyone with a high value would otherwise never know.
Blood pressure
The best-studied modifiable risk factor there is. It causes no symptoms for years and takes minutes to measure.
Plaque on vascular ultrasound
Shows whether the process has already begun. That changes the assessment in people whose laboratory values sit in a grey zone, and with it the treatment decision.
The limit
Even for the heart the evidence stops somewhere
That the chain closes for cholesterol and blood pressure does not mean every additional cardiac test carries the same benefit. For broad imaging in people without symptoms that evidence is missing, which is why a whole-body MRI sits at evidence tier 3 here. It can add structural information and triggers no treatment here.
That distinction is not a detail. It is the difference between a finding that leads somewhere and one that mainly creates unease.
Frequently asked questions
Partly yes, and cardiovascular disease is the area where this is best evidenced. The mechanism matters: the measurement does not prevent anything, it leads to a treatment that does. An analysis of 26 randomised trials with around 170,000 participants shows that lowering LDL cholesterol by 1 mmol/l reduces the rate of major vascular events by roughly a fifth. The same pattern holds for blood pressure. That completes the chain: finding, treatment, better outcome. It applies to the established risk markers, not automatically to every additional cardiac test.
Blood pressure, a lipid profile including ApoB, Lp(a) once, HbA1c and cardiorespiratory fitness. Those five cover the part with the best-evidenced benefit, and together they are neither expensive nor elaborate. ApoB is worth having alongside LDL because it counts the atherogenic particles and therefore reflects risk more precisely. Lp(a) is genetically determined and therefore only needs measuring once in a lifetime. Anyone who knows and tracks those five has covered the robust part of cardiac prevention.
No. The evidenced part of cardiac prevention runs through laboratory work, blood pressure, vascular ultrasound, ECG and exercise testing. A whole-body MRI sits at evidence tier 3 here: for people without symptoms its benefit is not established, and a finding from it triggers no treatment. It can add structural information, but it replaces none of the values above and does not demonstrably improve risk assessment. If you are coming purely because of your heart, you get the effective part without imaging.
For the basic values there is no reason to wait: blood pressure, lipid profile and HbA1c make sense from adulthood and are included in the statutory health examination from 35. Lp(a) once, the earlier the better, because the value does not change and the consequence has longer to work. Extended diagnostics becomes more relevant with age and with family history. Anyone with a parent or sibling who had an early heart attack should bring the timing forward rather than wait for an age threshold.
Sources
LDL cholesterol lowering and major vascular events, 26 randomised trials, around 170,000 participants
Cholesterol Treatment Trialists Collaboration, Lancet 2010One-off Lp(a) measurement in adult life, ApoB as a risk marker
ESC/EAS Dyslipidaemia Guidelines, Eur Heart J 2020
Read on
The framework this answer sits in, and the diagnostics behind it.
What prevention can prevent
Four disease areas along the same five-level ladder.
Cardiac check Berlin
The cardiac diagnostics in the programme, with process and scope.
Blood values and biomarkers
The complete panel register, with experimental markers flagged.
Our evidence classification
Why blood pressure and lipid profile sit at tier 1 and the MRI does not.
Performance diagnostics with blood analysis
VO2max and laboratory work on one day, brought together by physicians.
Prediabetes
The second area where the chain closes completely.
Do you know your five values?
15 minutes, free of charge. Bring any existing results. We will also tell you when your GP is the right next step for you.
★ 4,9 · 71+ Google-reviews · PKV, Beihilfe & bKV reimbursable
